Especialista en Endocrinología.
Hospital Médica Sur.
Cédula 11184265.
Elsayed NA, et al. American Diabetes Association. Obesity and Weight Management for the Prevention and
Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023. Diabetes Care 2023; 46 (Supplement_1):
S128–S139.
Klein S, et al. Why does obesity cause diabetes? Cell Metab. 2022 Jan 4;34(1):11-20.
ElSayed NA, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023.
Diabetes Care 2023. 2023 Jan 1;46(Suppl 1):S140-S157.
Pratley R, et al. PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2
diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6;394(10192):39-50.
Husain M, PIONEER 6 Investigators, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851.